. Out of 108 patients, 78% achieved complete remission (CR), and event-free survival (EFS) and survival rates (s.e., %) at 7 years were 40 (5) and 51% (6%), respectively. It indicated that mitoxantrone could be substituted for conventional anthracyclines in the treatment of childhood AML without inducing cardiotoxicity. The aim of the next EORTC 58921 trial was to compare the efficacy and toxicity of idarubicin vs mitoxantrone in initial chemotherapy courses, further therapy consisting of allogeneic bone marrow transplantation (alloBMT) in patients with an HLA-compatible sibling donor or chemotherapy in patients without a donor. Out of 177 patients, recruited between October 1992 and December 2002, 81% reached CR. Overall 7-year EFS and survival rates were 49 (4) and 62% (4%), respectively. Out of 145 patients who received the first intensification, 39 had a sibling donor. In patients with or without a donor, the 7-year disease-free survival (DFS) rate was 63 (8) and 57% (5%) and the 7-year survival rate was 78 (7) and 65% (5%), respectively. Patients with favorable, intermediate and unfavorable cytogenetic features had a 5-year EFS rate of 57, 45 and 45% and a 5-year survival rate of 89, 67 and 53%, respectively.
Introduction
The Children Leukemia Group (CLG) of the European Organization of Research and Treatment of Cancer (EORTC) has performed two acute myeloblastic leukemia (AML) trials (Table 1 ). The first trial 1 evaluated the acute and subacute cardiac toxicity of a BFM-derived treatment regimen 2 in which mitoxantrone (MTZ) was substituted for daunorubicin. Echographic evaluation of the shortening fraction (SF) failed to detect any cardiomyopathy within the first 3 years from diagnosis. The remission rate was 65% after induction and 77% after consolidation, which was comparable to that reported in other studies. [2] [3] [4] [5] The 3-year event-free survival (EFS) rate was 41%. Seven patients out of 84 in continuous complete remission (CR) displayed an isolated relapse in the central nervous system. We were unable to confirm the prognostic value of the FAB classification or of the WBC as previously reported by Creutzig et al. 6 Successful cytogenetic analysis was obtained in only 61% of patients included in this trial.
The aim of the subsequent EORTC 58921 study was initially to evaluate MTZ, the efficacy of which had been demonstrated in the previous clinical study, as compared to daunorubicin, in a controlled randomized trial. By that time however, promising results had already been reported from the use of another anthracycline, that is, idarubicin. Possible benefits related to this drug were low cardiotoxicity and pharmacokinetic characteristics allowing a good penetration into the cerebrospinal fluid (CSF) compartment. 7 In addition, several studies suggested that idarubicin was more efficacious than daunorubicin in adult patients with AML. [8] [9] [10] Therefore, it was decided to rather compare MTZ with idarubicin in the EORTC 58921 trial. Other changes were introduced in the treatment regimen: the consolidation course of EORTC 58872, comprising four fortnightly doses of MTZ and which had induced very severe and prolonged neutropenia, was deleted and a combination of highdose Ara-C and the anthracycline to which the patient had been randomized was substituted for it. 11, 12 The second intensification was the 'DCTER' course according to the CCG 2861 protocol. 4, 5 The third intensification remained identical to the second intensification of 58872. Maintenance therapy remained unchanged, except for the deletion of the anthracyclines. In patients with an HLA-identical sibling donor, allogeneic bone marrow transplantation (alloBMT) was scheduled after the first intensification.
An analysis of several prognostic factors was performed, including cytogenetic features. In the 58921 study, the value of early alloBMT vs chemotherapy was assessed on the basis of intention-to-treat 13 by comparing the outcome of the group of patients with an HLA-identical sibling ('donor' group) with that of patients without such a donor ('no donor') group.
Patients and methods
Design of the studies EORTC trial 58872 was a nonrandomized pilot study, the aim of which was to evaluate the feasibility and efficiency of a BFMlike regimen 2 in which MTZ was substituted for daunorubicin. EORTC 58921 was a prospective randomized phase III trial comparing the efficacy and the toxicity of idarubicin vs MTZ given in induction and first intensification. A second objective was to compare, on the basis of intention-to-treat principle, the outcome of patients according to the availability of an HLAcompatible sibling donor.
Eligibility
In both studies, all children less than 18 years of age and with newly diagnosed AML or high-risk myelodysplasias (MDS) were eligible. Patients with Down's syndrome were excluded. In study 58921, patients with acute promyelocytic leukemia were ineligible.
Diagnostic procedure
The diagnosis of AML, centrally reviewed, was established on the initial smears when more than 30% of blasts were counted in the marrow and was based on the cytological FAB classification. 14, 15 In study 58872, the cytogenetic analysis was not standardized. In the 58921 trial, it was standardized and more often performed. ISCN system was applied for cytogenetic classification. 16 Cytogenetics was centrally reviewed in the two studies. At least 20 analyzed metaphases were required to include a patient in the 'normal' karyotype (NN) group. As for the other EORTC AML studies, the subgroup 'complex abnormalities' was defined by the presence of at least four unrelated abnormalities. 17 The patients with unknown, not done or unsuccessful cytogenetics were grouped as 'unknown'.
Therapeutic scheme
The randomized study 58921 design is schematically shown in Figure 1 . Treatment schedules of trials 58872 and 58921 are detailed in Table 2 . See Supplementary Information.
Definitions
The stratification of patients in favorable (t(8;21), inv(16)), intermediate (normal karyotype) and unfavorable cytogenetic risk groups was according to Keating's criteria. 18 In the unfavorable group, we have further distinguished those with poor and those with very poor risk features (À5, 5q-, À7, 7q-and/or complex abnormalities). 18 Unequivocal involvement of the CNS required either the presence of at least 5 cells/mm 3 of CSF, with at least one cell identified as a blast by cytologic examination, or clinical and imaging evidence of intracranial leukemia. In the 58872 study, presence/absence of CNS involvement was decided on the basis of this definition of unequivocal involvement. In the 58921 study, we further defined 'surreptitious CNS involvement' as the presence of less than 5 nucleated cells/mm 3 in the CSF and of at least one blast. CNS involvement was considered as dubious in case of CSF with blood admixture and the presence of blasts. NCI criteria for response to treatment and relapse were used 19 (Supplementary Information).
Statistical analysis
The duration of survival was calculated from the date of registration until the date of death or last date of follow-up (for censored observations). For patients who reached CR, the duration of survival was calculated from the date of achievement of CR. The EFS was calculated from the date of CR to the date of first relapse or death in CR or last date of follow-up (for censored observations); patients who did not reach CR after the first intensification were considered as having an event at time zero. For patients who reached CR, the disease-free survival (DFS) was defined in the same way as EFS. Actuarial curves were calculated according to the Kaplan-Meier technique and the standard errors (s.e.) of the estimates were computed using the Greenwood formula. 20 The estimates of the incidence of relapse and of death in CR and their corresponding s.e. were obtained using the cumulative incidence method, risks of death in CR and of relapse being considered as competing risks. The differences between actuarial curves were tested for statistical significance using the two-tailed log-rank test for categorical variables and the log-rank test for linear trend for ordered variables. 20 The Cox proportional hazards model was used to obtain the estimate and the 95% confidence interval (CI) of the hazard ratio (HR) of the instantaneous event rate in one group vs that in another group, as specified by a given variable. 20 All analyses were based on the intent-to-treat principle. Further considerations can be found in Supplementary Information.
Patients
In study 58872, a total of 133 patients were registered: 124 with AML and nine with MDS. Only 124 AML patients have been analyzed for this report. A total of 16 ineligible patients have been excluded, whereas 108 children were considered as eligible and evaluable. 1 In study 58921, in order to perform a statistical evaluation on patients with at least 2 years of follow-up, only patients registered before 2001 have been included. Between its start in October 1992 and December 2000, a total of 200 patients were randomized in this study: 188 AML patients and 12 MDS patients. For this report, only the 188 AML patients have been considered. Of the 177 eligible and AML results: EORTC Children Leukemia Group N Entz-Werle et al evaluable children, 87 were randomized to MTZ and 90 to idarubicin. For each study, the patient characteristics are given in Table 3 . Analyzable karyotypes were available for 66 out of 108 patients in trial 58872 and for 139 out of 177 patients in study 58921. The patient distribution according to Keating classification is given in Table 3 .
Results

Response to induction and second course
The CR rate after one or two courses of chemotherapy was 78% in study 58872 and 84% in study 58921 trial (Table 4a ). The response rates restricted to patients o15-years old are indicated in Table 4b .
Overall outcome
The median follow-up was 5.2 years in the 58872 study and 5.5 years in the 58921 study. Table 4a and Figures 2 and 3 indicate the results regarding the overall survival and EFS. For patients who reached CR, the outcome at 5-7 years is indicated in Table 4a as well. The outcome restricted to patients o15 years old ('well-defined core-group of patients') 21 is indicated in Table 4b . AML results: EORTC Children Leukemia Group N Entz-Werle et al Among the patients with unfavorable risk features in the 58921 trial, those with a t(9;11) had a somewhat better outcome: eight out of nine patients achieved CR, three relapsed, and the 5-year EFS and survival rates were 56 and 67%, respectively. Patients aged 2-9 years and those with an initial leukocyte count less than 100 Â 10 9 /l had a better prognosis in terms of EFS and survival, but these differences were not significant and only studied in the 58921 cohort (Table 5) .
Initial CNS involvement was of no prognostic importance regarding either the EFS or the survival.
Outcome according to donor availability
The data on donor availability were prospectively collected in the 58921 study. Among 145 patients who reached CR and received the first intensification, 39 patients had an HLAidentical sibling donor ('donor' group) and 106 patients did not ('no donor' group). The characteristics of these two groups are indicated in Table 3 ; see also Supplementary Information.
In the 'donor' group, 33 were allografted in CR1, one after relapse and five received chemotherapy. In the 'no donor' group, 104 received a second intensification and 98 a third intensification.
For the DFS from CR according to donor availability (see Supplementary Figure 2 ), the estimated HR was 0.81, 95% CI (0.44, 1.47). The 5-year DFS rates and 5-year cumulative incidences of relapse and death in CR are indicated in Table 4a . In the 'donor' group, three patients died in CR1 after alloBMT, due to either infection, veno-occlusive disease or other cause, and five patients in the 'no donor' group: three after the second intensification, due to infection, CIVD or other cause; one patient during maintenance; and one after an unrelated alloBMT.
The duration of survival from CR according to donor availability is indicated in Figure 5 and Table 4a . The 5-year survival rate after relapse corresponding to 11 and 39 patients in the 'donor' and 'no donor' group, respectively, was 35 (716%) vs 20% (77%).
Toxicity
In study 58872, substitution of 3 Â 10 mg MTZ for 3 Â 45 mg daunorubicin during the induction phase did not seem to have (9) 10 (12) 1 (3) a Presence of À5, 5q-, À7, 7q-and/or complex abnormalities.
AML results: EORTC Children Leukemia Group N Entz-Werle et al Table 4 (a) Response to induction/intensification in whole population and outcome estimates (EFS and survival) by study; in patients who reached CR after induction/intensification, type of first event and outcome estimates; for patients who received intensification, these have been presented according to the availability of an HLA-identical sibling (study 58921 only). (b) In patients o15 years at diagnosis, response to induction/intensification in whole population and outcome estimates (EFS and survival) by study; in patients who reached CR after induction/ intensification, type of first event and outcome estimates 58872 study 58921 study AML results: EORTC Children Leukemia Group N Entz-Werle et al modified the duration or the severity of the postinduction aplasia: the median time to PMN40.5 Â 10 9 /l and platelets450 Â 10 9 /l was 4 weeks from the start of induction. In contrast, the consolidation course, which called for fortnightly MTZ in addition to vincristine, Ara-C and 6-thioguanine, induced very protracted and severe myeloid aplasia: the median time to PMN40.5 Â 10 9 /l was 12 weeks (range 4-18 weeks). Four patients died of infection following consolidation. Grade 3 and 4 toxicities are indicated in Supplementary Table 1. Transient decrease of the cardiac SF was observed in some patients after consolidation and intensification treatment phases, but echographic monitoring of the cardiac function after at least 3-year follow-up failed to reveal any significant cardiotoxicity. The grade 3 and 4 toxicities of treatment courses in trial 58921 are indicated in Supplementary Table 2 .
Discussion
The treatment regimen used in the EORTC 58872 study was adapted from the AML-BFM 83 protocol, 2 the results of which seemed to be the best of all at that time. There were two main modifications in EORTC 58872 as compared to the BFM protocol: the deletion of radiotherapy to the CNS in patients without CNS involvement and with less than 70 Â 10 9 /l leukocytes at diagnosis, and the substitution of MTZ for daunorubicin during induction, consolidation, first intensification and maintenance. At the time the study was designed, anthracyclines were considered to be a mandatory component of AML treatment regimen but the discovery of their late cardiotoxicity had become a matter of great concern. The objective of EORTC 58872 was to evaluate the efficacy and the acute and late toxicity of a BFM-like AML protocol in which 
55% (±5%)
Figure 2
Overall survival from start of treatment by study; the 5-year estimates rates (7s.e., %) are indicated. N ¼ number of patients; O ¼ observed number of deaths. 
40% (±5%)
Figure 3
Overall event-free survival from the evaluation of induction/intensification by study; the 5-year estimates rates (7s.e., %) are indicated. N ¼ number of patients; O ¼ observed number of events (lack of achievement of CR, relapse or death in first CR).
AML results: EORTC Children Leukemia Group N Entz-Werle et al daunorubicin was replaced by a hopefully less cardiotoxic anthracycline, that is, MTZ. Eventually, despite the high myelotoxicity of MTZ during the consolidation phase, the 5-year survival of 55% matched the results reported from the AML-BFM 83 study. 2 With regard to cardiotoxicity, no significant abnormality of the cardiac function was observed between 3 and 5 years of diagnosis. 1 In the treatment protocol of the following EORTC 58921 trial, several modifications were introduced: high-dose Ara-C was used earlier than in EORTC 58872, that is, in the first postinduction course, the long consolidation of the original AML-BFM 83 was deleted, the double DCTER course as used in CCG-2891 4, 5 was introduced as second postinduction course and cranial radiotherapy was further restricted to patients with initial unequivocal CNS involvement. In the course of the trial, it appeared that the toxicity of the DCTER when used as second intensification course was much more severe than that reported after the DCTER used as induction treatment. 4, 5 Therefore, this chemotherapy course consisting of two subsequent identical parts was reduced to only one of these. It is worthy of note that the immediate toxicity of the first intensification was not reduced after the total dose of Ara-C had been diminished from 36 to 24 g/m 2 (data not shown). With regard to efficacy of the 58921 protocol, the response rate (81% CR rate after the first intensification), the 5-year EFS rate (48%) and the 5-year survival rate (62%) are similar to those achieved in the previous 58872 study as well as those recently published by other groups. 5, 6, 22, 23 However, no conclusion can be drawn from any historical comparison as several factors may influence the outcome: distribution of prognostic factors, supportive care, treatment applicability, etc. Worthy of note is the low incidence of CNS relapses in 58921, whether isolated (2%) or combined (4%). The administration of high-dose Ara-C during the first and the third intensification and of repeated intrathecal injections of (5) 55 (5) 49 (4) 62 (4) Age (years) o2 48 (10) 63 (10) 46 (7) 56 (7) 2-9 33 (7) 48 (7) 55 (6) 72 (5) 10-17 47 (9) 60 (9) 44 (7) 52 (7) 10-14 48 (10) 63 (9) 41 (8) 52 (8) 15-17 33 (27) 33 (27) 55 (15) 55 (15) WBC (10 9 /l) o 20 41 (7) 57 (7) 51 (5) 62 (5) 20p100 37 (9) 53 (9) 47 (7) 62 (7) X100
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Figure 4
Survival from the start of treatment according to the Keating cytogenetic classification in the EORTC 58921 study. N ¼ number of patients; O ¼ observed number of deaths; P-value (log-rank test for linear trend). 
Figure 5
Survival from CR according to donor availability at the end of first intensification in the EORTC 58921 study. N ¼ number of patients; O ¼ observed number of deaths.
Ara-C in case of initial CNS involvement might have contributed to the eradication of CNS leukemic involvement.
The limited number of events reported so far does not allow us to disclose the results according to the randomized anthracycline in this subgroup of patients with a minimum 2-year followup. Nevertheless, we did evaluate the absolute and relative efficacy of the decision to commit patients with an HLAcompatible sibling donor to alloBMT. Owing to the insufficient number of events, no P-value has been given. The evaluation has been carried out according to the intention-to-treat principle, the intention being dictated by the availability or nonavailability of an HLA-identical sibling donor. The 5-year DFS rate was slightly higher in the group of patients with a donor as compared to those without a donor (63 and 57%, respectively). The 63% DFS rate is similar to the 60% DFS rate reported by Woods et al 5 for patients with a donor and committed to alloBMT in CCG 2891. In the latter trial, there was a significant difference in favor of the group with a donor in terms of DFS but the group with no sibling donor had a lower DFS (45%) than in EORTC 58921. The apparently better results in our study may be related to the use of a more intensive and more prolonged postinduction therapy.
In terms of survival, patients with a donor had a 7-year survival rate of approximately 8% higher than patients without donor (73 vs 65%, estimated HR of 0.64). The difference in survival was thus greater than that in DFS, which suggests that the salvage treatment after relapse (eg chemotherapy alone or alloBMT using a donor from a registry) was not more but actually less efficient in patients without a donor. The CCG also reported a 12% difference of survival rate at 8 years in favor of the group of patients with a sibling donor. 5 We have analyzed the prognostic importance of several initial factors. In contrast with the results reported by Chang et al, 24 in studies 58872 and 58921, age and initial leukocyte count did not seem to have an important prognostic impact. This might be due to the intensity of the treatment, although Wells et al 25 also failed to show any prognostic significance of these factors in CCG trial 213, whose overall results (7-year survival rate of 35%) did not match ours. The subgroups defined according to the FAB classification contained too few patients to provide meaningful analyses. In study 58921, patients with available and analyzable cytogenetic examination represented almost 80% of the total. All patients with good cytogenetic features (15% of the total) according to the Keating classification achieved CR, they had a 5-year EFS rate of 57% and a 5-year survival rate of 89%. Patients (N ¼ 11) with inv(16), generally classified as M4 with eosinophils, had the best outcome. Patients with intermediate-and poor-risk features did worse, as already described by other authors, but the 5-year survival rate was still higher than 50%. The relatively good outcome of patients in the unfavorable group may be related to the inclusion of patients with t(9;11) or with 7q-. It has recently been suggested that the presence of t(9;11) might indeed be of good prognosis. 26, 27 With regard to 7q-, there is also evidence that, in contrast to monosomy 7, it is of rather favorable prognosis.
28,29
Conclusion
MTZ is a safe substitute for classical anthracycline (study 58872). Restricted to this preliminary analysis of study 58921 to patients with at least 2-year follow-up, the data are too immature to allow a conclusion about the relative value of idarubicin vs MTZ. A trend toward longer DFS and survival has been observed in favor of patients with an HLA-identical sibling. Overall results of study 58921 look quite promising in all cytogenetic risk groups. In spite of the intensity of postremission treatment, whether it being alloBMT or further chemotherapy, its relatively low toxicities encourage us to pursue this therapeutic strategy.
